In a sweeping interview, Elon Musk positioned solar power as the indispensable core of future energy, AI, and space ambitions, praising China's manufacturing scale while urging a massive U.S. build-out.
Following the finalization of a joint venture with investment firm CPE, Burger King's parent company RBI has reaffirmed ambitious plans to more than triple its footprint in China over the next decade, backed by a $350 million investment.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Needham raises Nova Ltd. (NVMI) to Buy with a $500 price target, citing improving industry conditions and the company's strategic position in China's memory market. The upgrade follows a similar bullish move by Bank of America earlier in January.
Japan has successfully retrieved rare-earth-rich sediment from the deep Pacific seabed in a world-first test, marking a significant step in its national strategy to diversify critical mineral supplies and reduce dependence on China.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
India is negotiating with Ant International to link its Unified Payments Interface (UPI) with the Alipay+ network, a move that could simplify overseas transactions for Indian travelers and signal a thaw in economic relations with China, according to government sources.
A new survey by the American Chamber of Commerce in Hong Kong reveals a significant uptick in business optimism for 2026, with over half of senior executives expressing a positive outlook despite persistent U.S.-China tensions and global uncertainty.
Honda Motor posted a 4.3% year-on-year increase in global vehicle production for December 2025, recovering from a steep November slump. However, the automaker's full-year 2025 output fell nearly 9%, highlighting uneven regional performance with North America rebounding sharply while Asia, particularly China, saw significant declines.
A Beijing court has sentenced ex-Justice Minister Tang Yijun to life imprisonment on bribery charges, state media reported Monday, marking one of the highest-profile convictions in China's ongoing anti-corruption campaign.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Alibaba Group has pledged 3 billion yuan ($431 million) to promote its Qwen AI app during the upcoming Lunar New Year holiday, significantly outpacing similar campaigns by rivals Tencent and Baidu and marking a major escalation in China's competitive AI landscape.
